News: 12/20/24

Friday, December 20, 2024

How to Turn the AI Energy Crisis into BIG Profits

According to Elon Musk, the growth of AI is rising by a factor of 10 every six months. And he says this will create a major shortage of electricity.

President Trump agrees. "We have to produce massive electricity that we don't have," he says. "BUT... we will be able to do it."

How will Trump and Musk solve this problem?

The answer might surprise you. And investors who move now into one technology could make a whole lot of money.

This ad is sent on behalf of The Oxford Club. 105 W Monument St, Baltimore, Maryland 21201.
If you would like to opt out from receiving offers from The Oxford Club, click here.

IMPORTANT NOTICE AND DISCLAIMER
Investing Media Solutions, LLC ("IMS"), the owner of this website (the "Website"), cannot guarantee the accuracy or completeness of the information contained in any article, email, newsletter, or other publication posted on or viewed in connection with this website (the "Publications"). The author or authors of those Publications are solely responsible for their contents. IMS has not done any research or due diligence into the markets, industries, or companies which may appear or be mentioned in the Publications. IMS will NOT be liable for any loss or damage caused by a reader's reliance on information posted on the Website or contained in the Publications.

FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE.
This Website and the Publications are for educational and informational purposes only. This Website and the Publications do not purport to be a complete analysis of any company's financial position. This Website, the Publications or any statements made in the Publications are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. This Website or the statements made in the Publications should NOT be relied upon for purposes of transacting in any securities posted on the Website or mentioned in the Publications, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security posted on this Website or mentioned in any Publications.

SUBSTANTIAL RISK IN INVESTMENT.
Any individual who chooses to invest in any securities including those mentioned in the Publications should do so with caution. Investing or transacting in securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers bear responsibility for their own investment research and decisions and should review all investment decisions with a licensed or registered investment professional.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER
Neither IMS nor any of its respective owners or employees are registered or licensed as a securities broker-dealer, broker, an investment advisor, or an investment advisor representative with the U.S. Securities and Exchange Commission (SEC), any state securities regulatory authority, or any self-regulatory organization.

To more fully understand our Website, please review our full disclaimer located at: https://investingwealthdaily.com/disclaimer/

DISCLAIMER: Investing Wealth Daily is strictly a research publishing firm and much of the information we publish in email and our various websites are obtained from sources we believe to be reliable. You should know that accuracy can never be guaranteed. We do not design our content to meet your personal situation & you need to know we are absolutely not financial advisors and we never, under any circumstance give our users personalized advice. Every single opinion we express herein are those of the publisher and are subject to change without notice. Published content may become outdated and there is no obligation to update any such information.

This communication includes advertising material and PAID ADVERTISEMENTS provided to our customers. Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted. Sponsored emails, like this in Investing Wealth Daily or our other publications, contain paid advertisements and don't necessarily endorse or recommend it to you or any investor. Neither the company nor our affiliates bear responsibility or control over the content of the advertisement and the product or service offered. Proceed at your own risk. Privacy Policy

If you wish to contact us, please do not reply to this message but instead e-mail us at support@e.investingwealthdaily.com. Replies to this message may not be read or responded to. We are unable to respond to emails and phone calls requesting personal financial advice.

Sponsored emails, like this in Investing Wealth Daily or our other publications, contain paid advertisements and don't necessarily endorse or recommend it to you or any investor. Neither the company nor our affiliates bear responsibility or control over the content of the advertisement and the product or service offered. Proceed at your own risk.

At Investing Wealth Daily, it's our mission to create and provide a community that helps you live a more lucrative and enriched life. When Investing Wealth Daily was established a few years back, we wanted to make the community an inclusive, welcoming table where everyone can come to find investment trends! Over the years, and over 100 thousand combined followers across our social media platforms, we will always aim to get better at what we do every single day! In addition, our primary focus is on our relationship with you. This way every time you decide to visit one of our properties or read one of our relevant articles, you end up getting an idea that takes your investment portfolio to the next level. We particularly appreciate when our following provides feedback via testimonials, reviews, and comments left on our site or social media accounts. Because with that feedback, we can use it to make your next investment or stock purchase even better than the last! Since we put so much effort into the relationship with you, we hope that any time spent with us is exactly the way you hoped it would be. Because by choosing to go with Investing Wealth Daily, it's our promise that we provide a community you will love for years and years to come. Now, as much as we care about helping you make the right investments, we also care about your privacy. At Investing Wealth Daily transparency and the use of data are important and we would like to be as explicit as we can about the use of data collected through our platforms. Investing Wealth Daily is owned and operated by https://investingwealthdaily.com/. We're committed to the right of your privacy and strive to provide a safe and secure user experience. Our Privacy Policy explains how we collect, store and use personal information, provided by you on our website.

What Information Do We Collect?

When you visit our Web site you may provide us with two types of information: personal information you knowingly choose to disclose that is collected on an individual basis and Web site use information collected on an aggregate basis as you and others browse our Web site following all compliance standards.

For example, you may need to provide the following information:

Name
Website URL information
Email address
Home and business phone number

In addition to providing the foregoing information, if you choose to correspond further with us through email, we may retain the content of your email messages together with your email address and our responses securely within our systems. We provide the same protections for these electronic communications that we employ in the maintenance of information received by mail and telephone.

It also explains important information that ensures we won't abuse the information that you provide to us in good faith. By accessing and using our website, you can trust that what you want to be kept private, will be kept private. If at any time, you would like to read our Privacy Policy and get a better understanding of your rights and liabilities under the law. Feel free to visit our site, find the privacy policy in the footer and read it. If there is something you are concerned about or wish to get more clarity on, please let us know by contacting us at support@e.investingwealthdaily.com. The Privacy Policy also informs you of how to notify us to stop using your personal information. If you wish to view our official policies, please visit our website https://investingwealthdaily.com/ where you can find the latest information regarding data collection and use.

If you end up visiting https://investingwealthdaily.com/, we are strongly committed to protecting your privacy and providing a safe & high-quality online experience for all of our visitors. We understand that you care about how the information you provide to us is used and shared. We have developed a Privacy Policy to inform you of our policies regarding the collection, use, and disclosure of information we receive from users of our website. https://investingwealthdaily.com/ operates the Website. This privacy policy has been created to keep you informed about the steps we take once data is acquired. It is regularly updated to meet the needs of a changing technological environment ensuring its relevancy.

Our Privacy Policy, along with our Term & Conditions, governs your use of this site. By using https://investingwealthdaily.com/, or by accepting the Terms of Use (via opt-in, checkbox, pop-up, or clicking an email link confirming the same), you agree to be bound by our Terms & Conditions and our Privacy Policy.

If you have provided personal, billing, or other voluntarily provided information, you may access, review, and make changes to it via instructions found on the Website or by emailing us at support@e.investingwealthdaily.com. To manage your receipt of marketing and non-transactional communications, you may unsubscribe by clicking the "unsubscribe" link located on the bottom of any marketing email. By clicking the link you will be taken to a page where you may unsubscribe from future marketing emails. Your change in status may take up to seventy-two hours to be reflected within our system. Emails related to the purchase or delivery of orders are provided automatically – Customers are not able to opt-out of transactional emails. We will try to accommodate any requests related to the management of Personal Information in a timely manner. However, it is not always possible to completely remove or modify information in our databases (for example, if we have a legal obligation to keep it for certain timeframes, for example). If you have any questions, simply reply to this email or visit our website to view our official policies.

As an important reminder the ideas and opinions of the writers of the content shared should be taken for informational and entertainment purposes. Independent research is an important part of investing success and due diligence should be practiced. For use of personal information please read below and be advised on the data that we collect and how it will be used in the future. Within our content you will see advertisements that are clearly labeled identifying them as products or services offered by our advertising partners. These products and services are provided by our advertising partners and not by Investing Wealth Daily.

Investing Wealth Daily
203 N La Salle Street, Suite 2100 | Chicago, IL 60601

Unsubscribe Here

Which Mattress Is Best for Your Sleep Position?

As always our sleep guides are available 24/7 to chat.

860-815-8755

The Saatva Team

SMARTER LUXURY SLEEP

SHOP BY CATEGORY

MATTRESSES

FURNITURE & DECOR

BEDDING & BATH

SALE

As always our sleep guides are available 24/7 to chat.

860-815-8755

The Saatva Team

SMARTER LUXURY SLEEP

Saatva 19-02 Whitestone Expressway, Suite 201, Whitestone, NY 11357
Copyright © 2024 All rights reserved.

You have subscribed to promotional emails from Saatva and provided your email address to us when you registered or purchased from us.

The long and short(age)

Dec 20, 2024

View in browser

By David Lim and Lauren Gardner

Presented by PBM Accountability Project

Driving The Day

A sign with the company logo sits outside of the headquarters campus of Eli Lilly

Eli Lilly's diabetes and weight-loss drugs are no longer in short supply in the U.S., says the FDA. | Scott Olson/Getty Images

NEXT UP IN THE SHORTAGE WARS — The FDA on Thursday declared — again — that the two-year shortage of Eli Lilly’s diabetes and weight-loss drugs has ended. But the battle over the status of the supply of tirzepatide, the drug's generic name — and the ability of compounding pharmacies to make copies of the drugs — is far from over.

The Outsourcing Facilities Association, which represents large compounders and sued the FDA in October after it first said the shortage was resolved, signaled it will continue its legal battle. In a status report filed with a federal court in Texas on Thursday, the association and the FDA said they’d provide an update by Jan. 2 “addressing the next steps in this litigation,” which will likely involve a motion for preliminary injunction by the OFA.

“The agency’s decision to declare the shortage over based on the manufacturer’s say-so ignores the facts, violates the law, and puts patient access at risk,” Lee Rosebush, the group’s chair, said in a statement. “The OFA will continue its efforts to hold the FDA accountable for its obligations under law and duty to the patients who depend on it for access to medical treatments.”

The FDA has already suggested that, if the group files a preliminary injunction motion, it will pause enforcement of Thursday’s decision against compounders until the court resolves the case.

The FDA argument: In anticipation, the FDA outlined its procedural approach in the declaratory order it sent Lilly, noting the law doesn’t “explicitly” describe how the agency can determine whether a product is in shortage — or whether a shortage has ended — and thus is “more compatible with adjudication than with rulemaking.”

Notice-and-comment rulemaking would also conflict with the FDA’s ability to keep private the existence of a shortage — which is legally permissible if the agency thinks disclosure could harm public health — and with its consideration of confidential business information when making shortage decisions, Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a letter to the company.

Enforcement discretion: The FDA order includes grace periods for different-size compounders — 60 days for small pharmacies and 90 days for larger facilities whose products are subject to the agency’s manufacturing quality rules — meaning it won’t penalize them for continuing to dispense compounded tirzepatide to patients as they transition to Lilly’s products.

The Alliance for Pharmacy Compounding, another industry group, applauded the “off-ramp” but questioned the completeness of the data the FDA relied on to make its decision.

“We continue to hear from pharmacies that the FDA-approved tirzepatide drugs are not attainable from wholesalers in quantities needed to meet demand by patients transitioning from compounded to commercial versions of the drug,” APC CEO Scott Brunner said.

Meanwhile, a Lilly spokesperson called the decision “a critical step towards protecting patients from the dangers of counterfeit and compounded knockoffs.”

Semaglutide, the active ingredient in Novo Nordisk’s GLP-1 drugs, is still considered in shortage, but that could also soon change.

IT’S FRIDAY. WELCOME BACK TO PRESCRIPTION PULSE. Have thoughts on the year-end bill?

Send your thoughts and tips to David Lim (dlim@politico.com or @davidalim) and Lauren Gardner (lgardner@politico.com or @Gardner_LM).

In Congress

Elon Musk and President Donald Trump are seen at a campaign event.

Republicans revised their spending plan after Elon Musk, left, and President-elect Donald Trump signaled that they were unhappy with the GOP's original version. | Alex Brandon/AP

ABOUT THAT HEALTH DEAL — A slew of health care provisions, including pharmacy benefit manager reforms, an extension of the FDA’s pediatric priority review voucher program and an overhaul of drug patent rules to address overlapping patents to thwart competition, were dropped in a revised spending plan unveiled by House Republicans late Thursday afternoon.

But the bill failed to advance on the House floor that evening by a 174-235 vote, failing to meet a two-thirds bar for passage under a fast-track procedure. House Minority Leader Hakeem Jeffries told reporters the proposal was “laughable” before the vote.

The new bill came after President-elect Donald Trump and Elon Musk — the co-leader of the so-called Department of Government Efficiency — called on Republicans to kill a deal House Speaker Mike Johnson had negotiated with Democrats. The result? A package that simply extends a handful of health care programs until the end of March.

MAHA CAUCUS LAUNCHES — Senate Republicans are launching a Make America Healthy Again caucus to promote Robert F. Kennedy Jr.’s agenda — well before the chamber votes to install him as HHS secretary, POLITICO’s Daniel Payne writes.

Sens. Ron Johnson (R-Wis.), Cynthia Lummis (R-Wyo.), Roger Marshall (R-Kan.), Rick Scott (R-Fla.) and Tommy Tuberville (R-Ala.) are its founding members.

The group’s policy goals include promoting food and nonpharmaceutical interventions; encouraging agricultural practices that improve the nutritional value of food; and furthering efforts to research, prevent and treat chronic diseases.

A message from PBM Accountability Project:

Pharmacy benefit managers (PBMs) are taking advantage of Medicare and America’s seniors. It's time for Congress to act. Rein in PBMs by requiring them to increase transparency, share discounts with seniors, and delink PBM profits from the cost of medicines in Medicare. Congress must pass S. 2973 and S. 3430 this year. Learn more.

Eye on the FDA

MORE E-CIG WARNINGS — The FDA issued warning letters to eight online retailers and one manufacturer Thursday for selling or distributing flavored disposable e-cigarettes that the agency had authorized.

WHAT IS ‘HEALTHY’? The FDA wants food labeled “healthy” to be held to more rigorous nutrition standards, POLITICO’s Marcia Brown reports.

The much-anticipated change, initially proposed in 2022 and the first update since 1994, will prevent products like sweetened cereals, white fortified bread and highly sweetened yogurts from using the label, despite previously qualifying.

The rule, which will be published in the Federal Register on Dec. 27, will automatically qualify certain “nutrient-dense” foods for use of the “healthy” label. Those foods include low-fat dairy products, beans, lean game meat, olive oil and avocados. Under the regulation, foods must meet specific limits on salt, added sugar and saturated fat.

Public health groups largely praised the rule but noted it was voluntary.

"Nearly three decades since the original designation was created, it was past time to update the requirements based on the latest nutrition science," said American Heart Association CEO Nancy Brown in a statement.

AROUND THE AGENCIES

MASS COVID INJURY CLAIMS — A federal program created to compensate patients and families of those injured or killed by medical countermeasures, like drugs or vaccines, had many claims in response to the Covid-19 pandemic — about 27 times more claims than all the those submitted during the first decade of the program.

According to a Government Accountability Office report released Wednesday, the Countermeasures Injury Compensation Program received 13,333 claims, which were related to the pandemic, compared with 491 claims in the program’s first 10 years.

Why it matters: Many conservatives continue to rail against what they say were missteps in the Covid response, with some casting doubt on the safety and efficacy of the vaccine after reports of myocarditis — inflammation of the heart muscle — in some individuals. And Robert F. Kennedy Jr., President-elect Donald Trump’s pick to lead HHS, has criticized laws that protect vaccine manufacturers from liability lawsuits.

As of June, 75 percent of claims were still pending, according to the report. Of the 25 percent of claims completed, 3 percent were eligible for compensation, and 56 percent were related to Covid. HHS has paid roughly $6.5 million in compensation, mostly going toward eligible claims for serious injuries caused by the H1N1 vaccine, and $400,000 for injuries, including myocarditis, related to Covid.

According to the report, HHS officials said they had challenges processing the large number of claims due to staffing shortages, outdated information systems and limited scientific backing to base decisions on injuries related to Covid.

A message from PBM Accountability Project:

Pharma Moves

Dr. Bob Temple will retire from the FDA at the end of the year. He’s currently senior adviser for clinical science and senior adviser in the Office of New Drugs.

Document Drawer

The Justice Department sued CVS this week, alleging the company knowingly filled invalid opioid prescriptions that contributed to the country’s ongoing epidemic.

Medicaid gross spending on 12 diabetes and weight-loss drugs, including several GLP-1s, increased by 540 percent from 2019 to 2023, totaling $9.4 billion in 2023, HHS’ inspector general reports.

WHAT WE'RE READING

The CDC disclosed this week the first known case of severe illness from an avian flu infection in the U.S., Lauren and POLITICO’s Marcia Brown report.

Tobacco giant R.J. Reynolds lost an appeal Thursday of competitor Altria’s win in a patent case, Reuters reports.

A message from PBM Accountability Project:

There’s consensus in Congress – real PBM reform is needed NOW.

Both sides agree we need to: improve transparency, break the link that allows PBMs to tie their profits to the price of the drug, and force PBMs to share discounts with seniors.

Congress: It is time to finish the job and pass bipartisan senate bills 2973 and 3430. America’s seniors are counting on it. Learn more.